Research

Cambridge Hepatology Research Seminars

We hold a monthly seminar series of liver-related research on Zoom at 1700 on the second Tuesday of the month.

  • 14th February 2023, Emmanuel Selvaraj (Culver Lab), University of Oxford.

The complementary role of quantitative magnetic resonance imaging techniques for the assessment of primary sclerosing cholangitis

The Zoom details for this seminar are:

Join Zoom Meeting

https://zoom.us/j/91344602150?pwd=THJneFhXSUtpZk1KUjNmTGUxY3YxQT09

Meeting ID: 913 4460 2150

Passcode: 398255

Future scheduled seminars:

  • 14th March 2023, Jonathan Fallowfield, University of Edinburgh.

SteatoSITE: A gene-to-outcome data commons for NAFLD research

  • 9th May 2023, Kelvin Yin, (Martinez-Jimenez lab), Helmholtz Pioneer Campus, Munich.

Polyploidisation transcriptionally and genomically buffers phenotypic ageing in hepatocytes

  • 13th June 2023, Vasilis Galanakis, (Vallier lab), Stem Cell Institute, Cambridge.

Epithelial plasticity in the human liver during chronic liver disease progression

Zoom details for subsequent seminars will be posted here and mailed out. The timetable of speakers for the rest of the year can be found here.


Clinical studies and trials at Cambridge

NAFLD/NASH

See link

Primary biliary cholangitis

Primary sclerosing cholangitis

Autoimmune hepatitis

  • UK-AIH

Metabolic

Liver transplantation

HCC

IgG4

Portal hypertension

Registries studies


Clinical studies and trials at Basildon

Beta-blockers or Placebo for Primary Prophylaxis (BOPPP) of oesophageal varices trial

Double-blind, randomised, placebo-controlled, phase II dose-finding study comparing different doses of norucholic acid tablets with placebo in the treatment of primary biliary cholangitis in patients with an inadequate response to ursodeoxycholic acid (NUT-2)

ASEPTIC: Primary Antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis


Clinical studies and trials at Norwich 

REGENERATE 747-303 Phase 3 double-blind randomized long-term placebo controlled multicentre study evaluating the safety and efficacy of Obeticholic Acid in subjects with Nonalcoholic Steatohepatitis (SR)
(861) NUC-5 PSC Double-blind, randomized, placebo-controlled, phase 111 study comparing norurosodexycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis
MGL-3196 A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlld Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis
The SPRING Study A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL EVALUATING THE SAFETY AND EFFICACY OF CM-101 IN SUBJECTS WITH PRIMARY SCLEROSING CHOLANGITIS- THE SPRING STUDY
PLN-74809 A randomized, double-blind, dose-ranging, placebo-controlled, Phase 2a evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with primary sclersing cholangitis (PSC) and suspected liver fibrosis (INTEGRIS-PSC)
UK-AIH Cohort The United Kingdom Autoimmune Hepatitis Cohort (UKAIH): a multicentre platform for research and translational medicine
Research Study into the genetic causes of PSC A UK Collaborative Study to Determine the Genetic Basis of Primary Sclerosing Cholangitis (UK-PSC)
PaCE Molecular biomarkers in pancreatic cyst fluid to improve diagnostic accuracy and malignancy risk assessment
CALIBRE Study CArvediloL versus variceal Band ligation in primary pREvention of variceal bleeding in liver cirrhosis [closed to new recruitment as of late 2022]

Areas of research:

Autoimmune liver disease/PBC/PSC:  George Mells (Cambridge) and Simon Rushbrook (Norwich)

Hepatocellular carcinoma:  Matt Hoare (Cambridge), Vicky Snowdon (Cambridge)

NASH/alcohol:  Mike Allison (Cambridge)

Metabolic liver disease:  Bill Griffiths (Cambridge)

Liver transplantation: Gwil Webb (Cambridge) and Will Gelson (Cambridge)

Hepatitis:  Will Gelson (Cambridge)

Portal hypertension: Vicky Snowdon (Cambridge)

Pulmonary complications of liver disease: Sambit Sen (Luton)

Please make contact if you would like any details regarding the above.